This week's roundup of Houston innovators includes Ben Jawdat of Revterra, Pete O'Heeron of FibroBiologics, and Jay Manouchehri of Fluence Analytics. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health tech to clean energy — recently making headlines in Houston innovation.

Ben Jawdat, CEO and founder of Revterra

Ben Jawdat, CEO and founder of Revterra, joins the Houston Innovators Podcast. Photo via LinkedIn

Ben Jawdat founded Revterra in Houston based on a unique kinetic energy storage technology. The company has created away to better optimize existing grid-based electric vehicle charging ports while still minimizing a carbon footprint. The startup hopes to be a major player within the energy transition.

"We really want to be an enabling technology in the renewable energy transition," Jawdat says. "One part of that is facilitating the development of large-scale, high-power, fast-charging networks. But, beyond that, we see this technology as a potential solution in other areas related to the clean energy transition."

He shares more about what's next for Revterra on the podcast. Read more and listen to the episode.

Pete O'Heeron, CEO and chairman of FibroBiologics

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release. Read more.

Jay Manouchehri, CEO of Fluence Analytics

Fluence Analytics has exited to a multinational Japanese engineering and software giant. Image via FluenceAnalytics.com

Yokogawa, which has its US operations based in Sugar Land, acquired Fluence Analytics Inc. in a deal announced last week. The terms of the deal were not disclosed and, effective immediately, the company operate as Yokogawa Fluence Analytics. Jay Manouchehri, who joined the company in 2022, will continue to serve as CEO of the entity.

“Combining forces with Yokogawa Electric enables us to capture the full value of our unique data sets, and we can't wait to deliver this added value to our customers," Manouchehri says in a news release. "Together, we will enable autonomous operations and digital transformation in the polymer and biopharma industries."

Founded in 2012 in New Orleans, Fluence Analytics moved to Houston in 2021 following a $7.5 million venture capital raise led by Yokogawa Electric Corp., which has its North American headquarters in Sugar Land. Read more.

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

Houston biopharma company launches equity crowdfunding campaign

money moves

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


This week's roundup of Houston innovators includes Allie Danziger of Ampersand Professionals, Pete O'Heeron of Fibrobiologics, and Brandy Guidry of The Cannon. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health innovation to job training technology — recently making headlines in Houston innovation.

Allie Danziger, founder and CEO of Ampersand Professionals

After working with thousands of interns, Allie Danziger of Ampersand Professionals says she's now got a product to upskill and train new hires for employers. Photo courtesy of Ampersand

Allie Danziger is taking the workforce development programming she's created for training and matching interns with businesses to a whole new level. The new offering gives companies an opportunity to streamline their onboarding process with Ampersand's plug-and-play programming.

Danziger says usually new hires need the most experienced mentor or manager, but they don't usually get that support — especially when it comes to businesses that don't have their own built-out mentorship or training program.

"Ampersand’s new training product fills that gap — it gives employers of any size any easy solution to provide basic job readiness training to employees, access to our team of dedicated coaches, and a detailed report at the end of their training summarizing how their new hire did in the training and any trends recognized and tips for managing this employee based on what the platform uncovered," she says. "Businesses can also sign up for additional coaching sessions and customize training materials, as an add-on if interested." Click here to read more.

Pete O'Heeron, CEO and chairman of FibroBiologics

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

Fibroblasts have so much potential for a wide range of cell therapy treatments — the opportunities are endless, according to Pete O’Heeron, CEO, founder, and chairman of FiberBiologics, a Houston-based company that’s using fibroblast cell technology to treat a variety of chronic diseases.

With over 150 patents issued or pending, O'Heeron's team has the most intellectual property surrounding fibroblasts in the world and, while there is a lot of activity in the stem cell space, they are the leader when it comes to fibroblasts, he says. FiberBiologics is the name of the entity O'Heeron is hoping to take public by the end of the year, but the business originated as SpinalCyte, specializing in spinal treatment, before evolving into FibroGenesis as the technology began treating more parts of the body.

"With fibroblasts being the most common cell in the human body, you have to assume its involved in every process of the human body," O'Heeron says on last week's episode of the Houston Innovators Podcast. "There's literally not biological process in the body where fibroblasts are not involved." Click here to listen to the episode and read more.

​Brandy Guidry, Pearland navigator at The Cannon

The Pearland Innovation Hub celebrates its launch this month. Photo via pearlandinnovationhub.com

The Pearland Economic Development Corp. has launched the Pearland Innovation Hub, aimed at connecting small businesses with programs and services that are designed to contribute to their success.

The Pearland Innovation Hub is managed through a partnership between the Pearland Economic Development Corp. and The Cannon, a Houston-area business networking community for entrepreneurs, investors, and corporate innovators. For now, the hub does not officially have a physical space. The Cannon hired Brandy Guidry to run the Pearland hub. She has more than 17 years of experience in business operations; engineering; technical marketing; innovation; and strategic planning, project, and program management.

“The Pearland Innovation Hub is a groundbreaking initiative to support existing and aspiring small business owners,” Guidry adds. Click here to read more.


Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

Houston cell therapy company prepares to IPO, move into new facility

Houston Innovators Podcast episode 135

Stem cells have had their time in the spotlight for a while, and now it's time for fibroblasts to have their moment, according to Pete O’Heeron, CEO, founder, and chairman of FibroBiologics, a Houston-based company that’s using fibroblast cell technology to treat a variety of chronic diseases.

The two types of cells are the only ones that can be used in cell therapy for a regenerative treatment, meaning that specialists can take healthy stem cells and fibroblasts from a patient and inject them into a part of the body that needs it the most. And, according to O'Heeron and his team, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron on this week's Houston Innovators Podcast. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."

With over 150 patents issued or pending, O'Heeron's team has the most intellectual property surrounding fibroblasts in the world and, while there is a lot of activity in the stem cell space, they are the leader when it comes to fibroblasts, he says. FibroBiologics is the name of the entity O'Heeron is hoping to take public by the end of the year, but the business originated as SpinalCyte, specializing in spinal treatment, before evolving into FibroGenesis as the technology began treating more parts of the body.

"With fibroblasts being the most common cell in the human body, you have to assume its involved in every process of the human body," O'Heeron says. "There's literally not biological process in the body where fibroblasts are not involved."

The strongest treatments under FibroBiologics's umbrella are for degenerative disc disease, orthopedics, multiple sclerosis, and cancer. With these applications progressing, O'Heeron has imminent IPO plans for the company.

"We're in the process of getting the company public so that we can have access to the resources to do larger scale human trials. So, I think over the next year you'll see us launch at least two large scale human trials with fibroblast with the intention of submitting to the FDA for commercialization," O'Heeron says.

The company is in the process of building out a new 14,000-square-foot-space that will allow FibroBiologics to house its office, lab, and manufacturing space under one roof for the first time.

"These are fantastic robust cells, and we want to be able to control the quality and potency of them and how they ship out and how we're able to transfer those cells to the end user," O'Heeron says.

He shares more about the company and the impact he expects fibroblasts to have on cell therapy treatment. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Here are three of the latest updates on new execs and advisory appointments from two Houston startups and a local venture group. Photo via Getty Images

3 Houston organizations announce strategic appointments across biotech and VC

short stories

Five Houston innovators have new roles they're excited about this spring. From new advisory board members to c-level execs, here's who's moving and shaking in Houston innovation.

The Artemis Fund names new vice president of finance and operations

Adrienne Mangual has a background in finance and consulting. Photo courtesy of Artemis

The Artemis Fund, a venture capital firm that funds female-founded startups with technology solutions in fintech, e-commerce tech, and care-tech, has announced a new member of its leadership.

Adrienne Mangual is the new vice president of finance and operations at the firm, joining Artemis's co-founders and general partners, Stephanie Campbell, Leslie Goldman, and Diana Murakhovskaya, along with Austin-based Juliette Richert, a senior analyst.

Mangual received her MBA from Rice University in 2019 after working 15 years in finance roles at J.P. Morgan and Key Energy Services. Over the past few years, she's worked in consulting positions with startups and technology.

"This is an exciting time to join The Artemis Fund as the fund is growing and our reach is expanding and continuing to make an impact on female founders," Mangual tells InnovationMap. "I am looking forward to supporting existing and future female founders and working with Diana, Stephanie, and Leslie as part of the team making investment decisions for the fund."

FibroBiologics appoints scientific advisory board member

Former astronaut Kate Rubins, who's spent a total of 300 days in space, has joined the a Houston company's scientific advisory board. Photo courtesy of FibroBiologics

Houston-based clinical-stage therapeutics company FibroBiologics announced the appointment of Kathleen “Kate” Rubins, Ph.D., to its scientific advisory board. A microbiologist and NASA astronaut, Rubins has conducted medical research on earth at academic institutions as well as on board the International Space Station.

“We are honored to welcome Dr. Rubins to our SAB,” says Pete O’Heeron, CEO and chairman of FibroBiologics, in a news release. “She has distinguished herself in both terrestrial research at the Salk and Whitehead Institutes and through her ethereal work on the International Space Station.

"It’s rare to have such a unique perspective on microbiology," he continues. "Dr. Rubins joins a board of world-renowned scientists who will help to guide us as we advance fibroblast cell-based therapeutics through preclinical and clinical development. We are the only company focused on this unique opportunity in leveraging fibroblasts as treatments for chronic diseases and Dr. Rubins will be a key advisor in our pursuit to bring relief to the patients.”

In 2016, Rubins completed her first spaceflight on Expedition 48/49, where she became the first person to sequence DNA in space. Most recently, she served on the ISS as a flight engineer for Expedition 63/64. Across her two flights, she has spent a total of 300 days in space, the fourth most days in space by a U.S. female astronaut, according to the release.

Cemvita Factory hires, promotes within its leadership team

Tara Karimi, co-founder and CTO, stands with Cemvita Factory's two new hires and recently promoted employee. Photo courtesy of Cemvita

Cemvita Factory has made big moves in its leadership team. The low-carbon biotech and synthetic biology solution provider has recently made three strategic appointments: Charles Nelson was hired as chief business officer, Roger A. Harris was promoted to chief commercial officer, and Alex Juminaga was recruited as head of strain development.

“Scaling to meet market demand requires the right team at the right time,” says Tara Karimi, co-founder and CTO of Cemvita, in a news release. “With Charlie, Roger, and Alex’s leadership, we’re well-positioned for growth at a time when the demand for decarbonization solutions is greater than ever.”

With over 10 years in product development, engineering, and technology commercialization experience, Nelson will oversee all aspects of sales, business development, and customer success.

“At Cemvita, we create sustainable solutions to challenges across heavy industries,” says Nelson in the release. “Our goal is to reinvent heavy industries in ways that speak to the future, reduce companies’ carbon footprints, and even create jobs; I’m delighted to help lead the charge.”

Harris originally joined Cemvita as vice president of technology commercialization a year ago and has over two decades of experience in research and development, and engineering. In his new role, he is responsible for scaling and commercializing the startup's technology.

“Cemvita is positioned incredibly well to support heavy industry in efforts to innovate, and to help oil and gas diversify offerings and reduce dependency on carbon-intensive products,” says Harris in the release. “It is an exciting time and I’m thrilled to be with Cemvita.”

Lastly, Alex Juminaga will lead the Cemvita biofoundry’s production of novel biomolecules. He brings over a decade of laboratory experience — specializing in metabolic engineering, protein expression/purification, enzyme kinetics and binding assays, analytical chemistry, and more.

“The field of synthetic biology is just getting started, with thousands of microbes yet to be discovered,” says Juminaga. “I’m excited to work alongside the brilliant scientists at Cemvita as we uncover new microbiomes and new uses for these tiny treasures.”

This innovative health care company has announced some big moves. Photo via Fibrobiologics.com

Houston health care company raises $100M and plans to IPO

big moves

A clinical stage therapeutic company has made some big moves — with an even bigger one on the horizon.

FibroBiologics, which is developing fibroblast-based therapeutic cures for chronic diseases, announced $100 million in fresh funding resulting from an agreement with GEM Global Yield LLC SCS, a private investment group, with offices in New York and Paris. The funds will be distributed over a 36-month term following a public listing of FibroBiologics common stock.

According to a news release, "FibroBiologics will control the timing and maximum amount of the drawdown under this facility and has no minimum drawdown obligation." The IPO could include acquisition via SPAC.

"This Agreement with GEM helps secure additional funding to further develop cell therapy cures in Multiple Sclerosis, Degenerative Disc Disease and Cancer using fibroblast cells," says Pete O'Heeron, CEO and chairman of FibroBiologics, in the release. "This Agreement provides for a strong balance sheet upon public listing and positions FibroBiologics for the next stage of commercial development to deliver life-changing abatement for patients with incurable chronic diseases."

Founded earlier this year, FibroBiologics offices in Southeast Houston adjacent to the University of Houston-Clear Lake campus, where O'Heeron completed his Masters in Healthcare Administration.

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from synthetic biology to venture capital — recently making headlines in Houston innovation.

Gaurab Chakrabarti, the CEO and co-founder of Solugen

Gaurab Chakrabarti shared his entrepreneurial journey on the SXSW stage this year. Photo courtesy of the Greater Houston Partnership

Houston doesn't have too many unicorns — startups valued at $1 billion or more — in its innovation ecosystem, but Solugen, a sustainable chemicals company, is among the elite group. Gaurab Chakrabarti, the CEO and co-founder of the company, joined Houston House by the Greater Houston Partnership, to share his story on the SXSW stage.

“You do make your own luck, but you have to be putting in the work to do it," Chakrabarti says, adding that it's not an easy thing to accomplish. “There are things you can be doing to increase your luck surface area."

He shared several lessons he learned on his founder journey in the discussion. Read more.

Sandy Guitar, managing director of HX Venture Fund

Sandy Guitar shares some lessons learned from the fallout of Silicon Valley Bank. Photo via HXVF

Following the failure of Silicon Valley Bank, there's one thing Sandy Guitar can say has changed for Houston innovators: Bank diversification is going to be a must.

“We didn't think we needed one last week, but this week we know we need a resilience plan," she says, explaining that bank diversification is going to be added to "the operational due diligence playbook." Read more.

Cameron Owen, co-founder and CEO of rBIO

San Diego-based rBIO moved to Houston to take advantage of the growing ecosystem of biomanufacturing and synthetic biology. Photo courtesy of rBIO

Founded in San Diego, rBIO recently relocated to Houston and has big plans for settling in the city, says Cameron Owen, the company's co-founder and CEO.

“Companies from California like us and the coastal areas were converging here in Houston and creating this new type of bioeconomy,” he tells InnovationMap.

He shares that Houston wasn't originally on his radar, until it was. A visit turned into a relocation, and it's just the beginning for the biotech startup that's focused on using synthetic biology for pharmaceuticals. Read more.

Innovative company with ownable multi-use concept shares details on Houston facility opening

coming soon

To some, Houston’s lack of zoning laws is a beautiful thing. The first time Byron Smith visited the city, he remarked on seeing a church, school, office building, and strip club all in startlingly close proximity.

At the time, the Sydney-born entrepreneur, whose previous experience was primarily in the automotive industry, was living in New York. But he fell in love with Space City.

“I was like, ‘We need to be in Texas,” he recalls, referring to expanding his next venture, XSpace, to the Lone Star State.

XSpace is a multi-use commercial condo building that allows entrepreneurs to own a home for their business.

“We’re a cool warehouse space that you own,” Smith explains, calling it “evolutionary space” where a business can grow from the roots up.

Though his family business was commercial real estate, Smith first dipped his toe into working with buildings with last year’s opening of the first XSpace in Austin. The city became “a natural fit” for the first project because Smith identified it as “a little bit more receptive to new things.” But Houston was part of the plan from the very beginning.

Located at 7022 Old Katy Road — close to both an escape room and an Aston-Martin dealership, among other diverse businesses — the Houston XSpace’s 86 units are already between 20- and 30-percent pre-sold, says Smith.

Rendering courtesy of XSpace

Confirmed owners of the spaces include “car guys,” such as a car-wrapping business; media companies that plan to podcast from XSpace; and an interior design company. Smith says that he’s been impressed with Houston’s depth of market.

“We’re trying really hard not to be rich-guy car condo stuff,” explains Smith. “It’s about cool, interesting people who are successful or are going to be successful.”

Though multiple businesses will all operate in XSpace, don’t think of it as a coworking space. In fact, coworking space is just a component included in the package of what owners get when they purchase part of XSpace. That’s inside the Owner’s Lounge, a flexible 4,000-square-foot area.

Each unit has natural light, but also metered electric and hot and cold running water. The whole facility is air-conditioned and well-ventilated and offers 24/7 access. The building is triple-gated for optimum security and includes a backup generator to ensure that owners will be able to work even in the case of another power grid failure.

Smith says that groundbreaking for XSpace will take place in seven weeks. Likely, owners will be able to start moving into the building in the summer of 2024. Until then, Smith says to expect some “sexy announcements” about upcoming partnerships and additional XSpace sites.

Though Smith says that global expansion isn’t yet in the plans for XSpace, “North American domination” is.

“All the cool cities, we’re going to be there,” he says. And it was all inspired by the coolest city of all and its eclectic business landscape.

Rendering courtesy of XSpace

Houston maintains its top 3 position on ranking of cities that best attract biz

by the numbers

According to a recent report, Houston is still one of the top city in the United States for attracting new companies.

The ranking, which was researched and published by Site Selection Magazine, found that the Houston-The Woodlands-Sugar Land region attracted 255 business projects last year. This put the metro in the third place of the list that analyzed larger regions.

It's the third year in third place for Houston, and the city had a year over year improvement in number of deals; 2021 reported 213 new business projects in Houston. In fact, the top three cities – Chicago, Dallas, and Houston, respectively — has remained the same for all three years. For 2022, the Chicago metro garnered 448 projects, while Dallas-Fort Worth-Arlington reportedly had 426 projects.

The report also called out a recent statistic from Kastle Systems, which was based on building access control data. The stat found that among 10 major cities analyzed based on t week of February, Houston was one of three metros that had a returned-worker percentages higher than 50 percent.

According to the Greater Houston Partnership data, new business accounted for more than 50 percent of business announcements in 2022. GHP's data varied from Site Selection's due to a difference in reporting methods, but the organization's research identified 199 new business announcements in the Houston area in 2022.

The NBAs included new businesses, HQ announcements, and expansions. The GHP data included information about these deals' industry verticals — and the manufacturing sector accounted for almost a third of the total NBAs in 2022.

Chart via houston.org

The GHP also rounded up a few of the most prominate deals reported in their data. According to the Partnership, here were more details about these NBAs:

  • Orsted — an offshore wind developer from Denmark is expanding its presence in Texas by establishing a new office in the Woodlands. The move is expected to create up to 100 jobs in the region.
  • Syzygy Plasmonics — a Houston-based energy 2.0 company is expanding its operations to Pearland. The new location will serve as HQ, R&D, and manufacturing for its deep-decarbonization platform, creating up to 120 jobs.
  • Alfred Talke Logistic Services — a German logistics firm is establishing a new facility in the region, serving as its U.S. headquarters. This project represents a $25 million investment and will create 240 jobs.

Trevor Best, co-founder and CEO of Syzygy, first discussed the company's expansion last year on the Houston Innovators Podcast.

"What we're seeing is the market's appetite for our kind of technology — deep tech for decarbonization in energy and chemicals — is really high. If we want to meet global demand for our product, we need to get ready to scale," he says on the show.